Drugmaker Eli Lilly & Co. announced on April 7 that it has rolled out a scheme to cap the out-of-pocket cost for insulin at $35, a move which will ease the financial burden on diabetes patients across the United States who may be struggling amid the CCP virus pandemic.
The co-pay scheme, titled the Lilly Insulin Value Program, is effective April 7 and allows those with commercial insurance, or no insurance, to purchase their insulin prescriptions for $35 per month. The initiative covers the majority of the drugmaker’s insulins, including widely-used Humalog injections.
